Skip to main content
SpringerLink
Log in

Systemic Treatment Drugs/Regimens and Dose Modifications

  • Chapter
  • First Online:
Breast Disease

  • 859 Accesses

Abstract

This chapter discusses chemotherapy regimens and targeted options for breast cancer treatment. Dose-limiting toxicities for targeted therapies are often markedly different from those of classic cytotoxic chemotherapy agents. This chapter briefly summarizes the recommendations for dose modifications of some new drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute.

    Google Scholar 

  2. Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, et al. Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 30(10):870–84.

    Article  CAS  Google Scholar 

  3. Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I, et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res. 2016;18(1):67. https://doi.org/10.1186/s13058-016-0721-5.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–7. https://doi.org/10.1093/annonc/mdy155.

  5. Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast Cancer. J Clin Oncol. 2017;35(32):3638–46. https://doi.org/10.1200/JCO.2017.75.6155. Epub 2017 Oct 2.

    Article  CAS  PubMed  Google Scholar 

  6. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast Cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–33.

    Article  CAS  Google Scholar 

  7. Tiwari SR, Mishra P, Abraham J. Neratinib, a novel HER2-targeted tyrosine kinase inhibitor. Clin Breast Cancer. 2016;16(5):344–8.

    Article  CAS  Google Scholar 

  8. Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367–77.

    Article  CAS  Google Scholar 

  9. Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus Capecitabine in women with HER-2-positive advanced breast Cancer: final survival analysis of a phase III randomized TriaL. Oncologist. 2010;15(9):924–34.

    Article  CAS  Google Scholar 

  10. Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, et al. Lapatinib plus Capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast Cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64–71.

    Article  CAS  Google Scholar 

  11. Tykerb (lapatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017.

    Google Scholar 

  12. Child CGIII, Turcotte JG. Surgery and portal hypertension. In: Child CGIII, editor. The liver and portal hypertension. Philadelphia: WB Saunders; 1964. p. 50.

    Google Scholar 

  13. Isakoff SJ, Baselga J. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2011;29(4):351–4. Epub 2010 Dec 20.

    Article  CAS  Google Scholar 

  14. Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE Study. J Clin Oncol. 2017;35(2):141. Epub 2016 Nov 7.

    Article  CAS  Google Scholar 

  15. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006;24(25):4107–15.

    Article  CAS  Google Scholar 

  16. Mackey JR, Clemons M, Côté MA, Delgado D, Dent S, Paterson A, et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab working group. Curr Oncol. 2008;15(1):24–35.

    Article  CAS  Google Scholar 

  17. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. CLEOPATRA study group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–34.

    Article  CAS  Google Scholar 

  18. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. EMILIA study group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Internal Medicine, Istanbul University Istanbul Medical Faculty, Institute of Oncology, Istanbul, Turkey

    Naziye Ak

  2. Oncology Institute, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

    Adnan Aydiner

Authors
  1. Naziye Ak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adnan Aydiner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oncology Institute, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

    Adnan Aydiner

  2. Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

    Abdullah Igci

  3. Division of Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, Magee-Women’s Hospital of UPMC, Pittsburgh, PA, USA

    Atilla Soran

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ak, N., Aydiner, A. (2019). Systemic Treatment Drugs/Regimens and Dose Modifications. In: Aydiner, A., Igci, A., Soran, A. (eds) Breast Disease. Springer, Cham. https://doi.org/10.1007/978-3-030-16792-9_51

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16792-9_51

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16791-2

  • Online ISBN: 978-3-030-16792-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation